Rigel Pharmaceuticals (RIGL) Net Income towards Common Stockholders (2010 - 2026)

Rigel Pharmaceuticals' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at $8.7 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 24.39% year-over-year to $8.7 million; the TTM figure through Mar 2026 stood at $364.2 million (up 879.7% YoY), while the FY2025 annual figure was $367.0 million, up 1999.08% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $8.7 million, down from $268.1 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $268.1 million in Q4 2025, with the low at -$27.4 million in Q1 2022.
• The 5-year median for Net Income towards Common Stockholders is -$61000.0 (2023), against an average of $18.2 million.
• The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders sank 169.48% in 2022, then soared 23609.84% in 2024.
• Rigel Pharmaceuticals' Net Income towards Common Stockholders stood at $1.4 million in 2022, then slumped by 104.35% to -$61000.0 in 2023, then jumped by 23609.84% to $14.3 million in 2024, then jumped by 1769.22% to $268.1 million in 2025, then sank by 96.77% to $8.7 million in 2026.
• Business Quant data shows RIGL's Net Income towards Common Stockholders at $8.7 million in Q1 2026, $268.1 million in Q4 2025, and $27.9 million in Q3 2025.